Clinical trial
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal…
NCT00128843 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00128843 |
|---|---|
| Title | Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients |
| Official title | Phase II Randomized, Multicenter, Crossover Clinical Trial for Administration of Exemestane vs. Anastrozole as First Line Treatment for Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Exemestane, Anastrozole |
| Enrollment | 103 |
| Start date | Aug 1, 2001 |
| Primary completion | Jul 1, 2005 |
| Completion | Oct 1, 2014 |
| First posted | Aug 10, 2005 |
| Last update posted | Mar 6, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: